title: Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
abstract: Increasing scientific evidence suggests that ribonucleotide reductase M1 (RRM1) may be a powerful predictor of survival in patients with pancreatic cancer treated with adjuvant gemcitabine-based chemotherapy after operative resection, but many existing studies have yielded inconclusive results. This meta-analysis aimed to assess the prognostic role of RRM1 in predicting survival in patients with pancreatic cancer treated with gemcitabine. An extensive literature search for relevant studies was conducted on PubMed, Embase, Web of Science, Cochrane Library, and CBM databases from their inception through May 1st, 2013. This meta-analysis was performed using the STATA 12.0 software and crude hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Eight clinical studies were included in this meta-analysis with a total of 665 pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy, including 373 patients in the high RRM1 expression group and 292 patients in the low RRM1 expression group. Our meta-analysis revealed that high RRM1 expression was associated with improved overall survival (OS) of pancreatic cancer patients (HR=1.56, 95%CI=0.95-2.17, P<0.001). High RRM1 expression also was linked to longer disease-free survival (DFS) than low RRM1 expression (HR=1.37, 95%CI=0.25-2.48, P=0.016). In conclusion, our meta-analysis suggests that high RRM1 expression may be associated with improved OS and DFS of pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy. Detection of RRM1 expression may be a promising biomarker for gemcitabine response and prognosis in pancreatic cancer patients.
authors.affiliation: Department of Laboratory Medicine, Hubei Wuchang Hospital, Wuhan, Hubei, China.
authors.forename: Xiong
authors.initials: X
authors.lastname: Zhang
authors.forename: Fen-Shu
authors.initials: FS
authors.lastname: Jin
authors.forename: Li-Guo
authors.initials: LG
authors.lastname: Zhang
authors.forename: Rui-Xue
authors.initials: RX
authors.lastname: Chen
authors.forename: Jin-Hui
authors.initials: JH
authors.lastname: Zhao
authors.forename: Yan-Nan
authors.initials: YN
authors.lastname: Wang
authors.forename: En-Fu
authors.initials: EF
authors.lastname: Wang
authors.forename: Zhen-Dong
authors.initials: ZD
authors.lastname: Jiang
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D011379:Prognosis; D012262:Ribonucleoside Diphosphate Reductase; D015996:Survival Rate; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D025521:Tumor Suppressor Proteins; D003841:Deoxycytidine; C475286:RRM1 protein, human; D012262:Ribonucleoside Diphosphate Reductase; D000093542:Gemcitabine